Showing results (111-120 of 171) with videos related to
Sort By:
Pageof 18
Clinical and Translational Science|July 10, 2017
Intra-Target Microdosing - A Novel Drug Development Approach: Proof of Concept, Safety, and Feasibility Study in HumansT Burt, D MacLeod, K Lee, et al.Cancer Prevention Research (Philadelphia, Pa.)|April 1, 2010
Energy balance, the PI3K-AKT-mTOR pathway genes, and the risk of bladder cancerJie Lin, Jianming Wang, Anthony J Greisinger, et al.Carcinogenesis|February 10, 2012
Genetic variants within ultraconserved elements and susceptibility to right- and left-sided colorectal adenocarcinomaMoubin Lin, Cathy Eng, Ernest T Hawk, et al.Clinical Trials (London, England)|February 8, 2017
Building trust and diversity in patient-centered oncology clinical trials: An integrated modelThelma C Hurd, Charles D Kaplan, Elise D Cook, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 10, 2008
The Translational Research Working Group developmental pathways: introduction and overviewErnest T Hawk, Lynn M Matrisian, William G Nelson, et al.Oncology (Williston Park, N.Y.)|October 1, 1996
Strategies for identification and clinical evaluation of promising chemopreventive agentsG J Kelloff, E T Hawk, J A Crowell, et al.Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|June 1, 1999
Lipoxygenase inhibitors as potential cancer chemopreventivesV E Steele, C A Holmes, E T Hawk, et al.Cancer Metastasis Reviews|August 17, 2018
Bioactive lipid metabolism in platelet "first responder" and cancer biologyPreeti Kanikarla-Marie, Scott Kopetz, Ernest T Hawk, et al.Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|March 4, 2000
Perspectives on surrogate end points in the development of drugs that reduce the risk of cancerG J Kelloff, C C Sigman, K M Johnson, et al.Expert Opinion on Investigational Drugs|November 4, 2000
Potential use of lipoxygenase inhibitors for cancer chemopreventionV E Steele, C A Holmes, E T Hawk, et al.Pageof 18